Afatinib Plus Bevacizumab After Acquired Resistance to EGFR-TKI in EGFR-mutant NSCLC
Phase of Trial: Phase II
Latest Information Update: 07 Sep 2018
Price : $35 *
At a glance
- Drugs Afatinib (Primary) ; Bevacizumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ABC-study
- 07 Sep 2018 Results published in the Cancer
- 24 Dec 2017 Status changed from recruiting to completed.
- 02 Jun 2017 Results (n=33) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.